Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0268596 (
EMA
)
2,520
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
High prevalence of coeliac disease (CD) has been reported in various autoimmune disorders, buthas not been studied in the
antiphospholipid syndrome
(
APS
). We aimed to establish the prevalence of CD antibodies in a cohort of
APS
patients, and to examine whether CD may be responsible for some of the manifestations of
APS
. Fifty-seven patients (47 females, 10 males) with
APS
were studied for clinical manifestations and serological markers of the disease, as well as the presence of anti-endomysial antibodies using an ELISA assay (EMA-ELISA). Control subjects were 171 healthy individuals, age- and sex-matched (141 females). Eight patients with
APS
(14%, six females) were found to have
EMA
-ELISA antibodies, compared with 2/141 (1.1%) of controls (P = 0.0003). Antibodies against beta2-glycoprotein-I (beta2GPI) epitopes (GRTCPKPDDLP) were more prevalent in
EMA
-positive patients than in
EMA
-negative patients (P = 0.006). Vasculitic skin lesions were significantly more common in
EMA
-ELISA-positive compared with
EMA
-ELISA-negative patients(62.5 versus 16.3%, P = 0.01). Among the skin manifestations, superficial cutaneous necrosis (37.5 versus 2%, P = 0.007) was more prevalent in
EMA
-ELISA-positive than in
EMA
-ELISA-negative patients.
EMA
-ELISA antibodies are common in
APS
, and their presence is associated with high prevalence of antibodies recognizing certain beta2-glycoprotein epitopes, and with cutaneous manifestations of
APS
.
...
PMID:The prevalence of coeliac disease antibodies in patients with the antiphospholipid syndrome. 1511 53